Avineesh Singh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11941591/publications.pdf

Version: 2024-02-01

		1163117	1474206
9	172	8	9
papers	citations	h-index	g-index
9	9	9	341
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Appraisal of pyrrole as connecting unit in hydroxamic acid based histone deacetylase inhibitors: Synthesis, anticancer evaluation and molecular docking studies. Journal of Molecular Structure, 2021, 1240, 130590.	3.6	6
2	Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies. Current Computer-Aided Drug Design, 2019, 15, 145-166.	1.2	8
3	The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies. Current Cancer Drug Targets, 2018, 18, 720-736.	1.6	18
4	Combretastatin A-4 based thiophene derivatives as antitumor agent: Development of structure activity correlation model using 3D-QSAR, pharmacophore and docking studies. Future Journal of Pharmaceutical Sciences, 2017, 3, 71-78.	2.8	10
5	Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects. Current Cancer Drug Targets, 2017, 17, 456-466.	1.6	14
6	Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. Oncology and Therapy, 2016, 4, 73-89.	2.6	30
7	Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents. Combinatorial Chemistry and High Throughput Screening, 2016, 19, 735-751.	1.1	18
8	Development of Structure Activity Correlation Model on Azetidin-2-ones as Tubulin Polymerization Inhibitors. Letters in Drug Design and Discovery, 2015, 12, 351-365.	0.7	9
9	Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers. Current Pharmaceutical Design, 2013, 19, 1923-1955.	1.9	59